High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Cancer Research

• Publication date

  1999-11-15

• Fields of study

  Medicine, Engineering

• Identifiers
  PMID 10582696
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering.

  1999cited by this paper
• Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)–carbonyl complex

  1999influential reference
• Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.

  1998cited by this paper
• Selection for a periplasmic factor improving phage display and functional periplasmic expression

  1998cited by this paper
• An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly

  1998cited by this paper
• Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas

  1998cited by this paper
• An intrinsically stable antibody scFv fragment can tolerate the loss of both disul¢de bonds and fold correctly

  1998cited by this paper
• KSA Antigen Ep-CAM Mediates Cell–Cell Adhesion of Pancreatic Epithelial Cells: Morphoregulatory Roles in Pancreatic Islet Development

  1998cited by this paper
• Antibody engineering.

  1998cited by this paper
• Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue.

  1998cited by this paper
• High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting.

  1998cited by this paper
• Antibody scFv fragments without disulfide bonds made by molecular evolution.

  1998cited by this paper
• The nature of antibody heavy chain residue H6 strongly influences the stability of a VH domain lacking the disulfide bridge.

  1998cited by this paper
• New protein engineering approaches to multivalent and bispecific antibody fragments.

  1997influential reference
• Antibody Humanization Using Monovalent Phage Display*

  1997cited by this paper
• Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting.

  1997influential reference
• Engineering antibodies for imaging and therapy.

  1997cited by this paper
• A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer

  1997cited by this paper
• Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system.

  1997influential reference
• Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library

  1996influential reference
• Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library

  1996cited by this paper
• The FSSP database: fold classification based on structure-structure alignment of proteins

  1996cited by this paper
• Selection of Linkers for a Catalytic Single-chain Antibody Using Phage Display Technology*

  1996cited by this paper
• Multicopy suppressors of prc mutant Escherichia coli include two HtrA (DegP) protease homologs (HhoAB), DksA, and a truncated R1pA

  1996cited by this paper
• Pharmacokinetics and scintigraphy of indium-111-DTPA-MOC-31 in small-cell lung carcinoma.

  1995cited by this paper
• Engineered turns of a recombinant antibody improve its in vivo folding.

  1995influential reference
• Preparation, characterization and crystallization of an antibody Fab fragment that recognizes RNA. Crystal structures of native Fab and three Fab-mononucleotide complexes.

  1995cited by this paper
• Thermal stabilization of a single‐chain Fv antibody fragment by introduction of a disulphide bond

  1995cited by this paper
• SCLC‐cluster‐2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP‐2

  1994cited by this paper
• Making antibodies by phage display technology.

  1994cited by this paper
• Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma

  1994cited by this paper
• Epitope mapping of SCLC‐cluster‐2 MAbs and generation of antibodies directed against new EGP‐2 epitopes

  1994cited by this paper
• Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

  1994cited by this paper
• Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group.

  1994cited by this paper
• Crystal structure of an anticholera toxin peptide complex at 2.3 A.

  1993cited by this paper
• Structural patterns at residue positions 9, 18, 67 and 82 in the VH framework regions of human and murine immunoglobulins.

  1993influential reference
• Humanized antibodies.

  1993cited by this paper
• Medical applications of single-chain antibodies.

  1993cited by this paper
• X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling.

  1993cited by this paper
• High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment

  1992cited by this paper
• Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex.

  1992cited by this paper
• Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface.

  1992cited by this paper
• Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor.

  1992cited by this paper
• Recursive PCR: a novel technique for total gene synthesis.

  1992cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Sequences of proteins of immunological interest

  1991cited by this paper
• Crystal parameters and molecular replacement of an anticholera toxin peptide complex

  1991cited by this paper
• Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma.

  1990cited by this paper
• Assembly of a functional immunoglobulin Fv fragment in Escherichia coli.

  1988cited by this paper
• Single-chain antigen-binding proteins.

  1988cited by this paper
• Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

  1988cited by this paper
• Three-dimensional structure of a complex of antibody with influenza virus neuraminidase

  1987cited by this paper
• The relation between the divergence of sequence and structure in proteins.

  1986cited by this paper
• Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

  1984cited by this paper

• Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering

  2025cites this paper
• Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

  2025influential citation
• Preparation, Characterization, and Radiolabeling of Anti-HER2 scFv With Technetium Tricarbonyl and Stability Studies.

  2024cites this paper
• Sequence tolerance of immunoglobulin variable domain framework regions to noncanonical intradomain disulfide linkages

  2023cites this paper
• Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

  2023cites this paper
• Epitope Mapping of an Anti-EpCAM Monoclonal Antibody (EpMab-37) Using the Alanine Scanning Method

  2023cites this paper
• Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells

  2023cites this paper
• Ligand-based targeting of c-kit using engineered γδ T cells as a strategy for treating acute myeloid leukemia

  2023cites this paper
• A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mG2a-f) Exerts Antitumor Activity in Xenograft Model

  2022cites this paper
• The B1 Domain of Streptococcal Protein G Serves as a Multi-Functional Tag for Recombinant Protein Production in Plants

  2022cites this paper
• Engineering Strategies to Overcome the Stability–Function Trade-Off in Proteins

  2022cites this paper
• An adapted consensus protein design strategy for identifying globally optimal biotherapeutics

  2022cites this paper
• An Anti-EpCAM Monoclonal Antibody (EpMab-37-mG 2a -f) Exerts Antitumor Activity against Breast Cancer in Mouse Xenograft Model

  2022cites this paper
• Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30

  2021cites this paper
• Reversible Shielding and Immobilization of Liposomes and Viral Vectors by Tailored Antibody-Ligand Interactions.

  2021cites this paper
• Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing

  2021cites this paper
• Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics

  2021cites this paper
• Statistical optimization of culture conditions for expression of recombinant humanized anti-EpCAM single-chain antibody using response surface methodology

  2021cites this paper
• Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells

  2021cites this paper
• Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin

  2021cites this paper
• Nanobodies: The “Magic Bullets” in therapeutics, drug delivery and diagnostics

  2020cites this paper
• Effective Strategies to Overcome the Insolubility of Recombinant ScFv Antibody against EpCAM Extracellular Domain in E. coli

  2020cites this paper
• Vascular Endothelial Growth Factor Receptor 3

  2020cites this paper
• Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape

  2020cites this paper
• Effective Strategies to Overcome the Insolubility of Recombinant ScFv Antibody against EpCAM Extracellular Domain in E. coli

  2020cites this paper
• Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response

  2020cites this paper
• Development of a CD22-specific chimeric antigen receptor (CAR) for the adoptive T cell therapy of leukemia and lymphoma

  2020cites this paper
• Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.

  2019cites this paper
• Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting

  2019cites this paper
• Evaluation of a noncanonical Cys40‐Cys55 disulfide linkage for stabilization of single‐domain antibodies

  2019cites this paper
• Hot CoFi Blot: A High-Throughput Colony-Based Screen for Identifying More Thermally Stable Protein Variants.

  2019cites this paper
• Yeast Cell Surface Engineering

  2019cites this paper
• Design, Expression, Purification and Characterization of the Recombinant Immunotoxin 4D5 scFv-TRAIL

  2019cites this paper
• Antibody-Fragments: Protein Engineering, Process Development, and their Application as Affinity Ligands

  2019cites this paper
• High level expression and characterization of the recombinant immunotoxin DAB389-4D5 scFv targeting HER2/neu-positive ovarian carcinoma cells

  2019cites this paper
• MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM

  2019cites this paper
• Engineering Antibodies and Alternative Binders for Therapeutic Uses

  2019cites this paper
• Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting

  2019cites this paper
• Design and Production of Bispecific Antibodies

  2019cites this paper
• Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation.

  2019cites this paper
• ساخت سویه بیانی پیکیا پاستوریس مولد قطعهی تکزنجیرهای ناحیهی متغیر آنتیبادی علیه ناحیه خارج سلولی EpCAM

  2019cites this paper
• Engineered Charge Redistribution of Gp2 Proteins through Guided Diversity for Improved PET Imaging of Epidermal Growth Factor Receptor.

  2018cites this paper
• Rapid Selection of High-Affinity Antibody scFv Fragments Using Ribosome Display.

  2018cites this paper
• Third generation antibody discovery methods: in silico rational design.

  2018cites this paper
• FoldX as Protein Engineering Tool: Better Than Random Based Approaches?

  2018cites this paper
• ON IMMUNOREHABILITATION

  2018cites this paper
• Entwicklung und Charakterisierung verschiedener neuartiger bispezifischer Antikörper basierend auf PankoMab-GEX™ zur Verbesserung der Tumortherapie

  2018cites this paper
• The antigenicity and cholesteroid nature of mycolic acids determined by recombinant chicken antibodies

  2018cites this paper
• Evaluation of affibody charge modification identified by synthetic consensus design in molecular PET imaging of epidermal growth factor receptor.

  2018cites this paper
• Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum

  2018cites this paper
• Simulation and Stability Assessment of Anti-EpCAM Immunotoxin for Cancer Therapy

  2018cites this paper
• Site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals

  2018cites this paper
• Fv-clasp: An Artificially Designed Small Antibody Fragment with Improved Production Compatibility, Stability, and Crystallizability.

  2017cites this paper
• Free Energy Perturbation Calculations of the Thermodynamics of Protein Side-Chain Mutations.

  2017cites this paper
• Development of T cell based therapeutic strategies for childhood cancer neuroblastoma

  2017cites this paper
• Targeted and theranostic applications for nanotechnologies in medicine

  2017cites this paper
• A disulfide-stabilized human VL single-domain antibody library is a source of soluble and highly thermostable binders.

  2017cites this paper
• Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis

  2017influential citation
• Complementarity determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv

  2017cites this paper
• Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells

  2016cites this paper
• Single-domain antibody based thermally stable electrochemical immunosensor.

  2016cites this paper
• Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments

  2016cites this paper
• Nanoyeast and Other Cell Envelope Compositions for Protein Studies and Biosensor Applications

  2016cites this paper
• Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing’s sarcoma

  2016cites this paper
• The Past, Current Studies and Future of Organometallic 99mTc(CO)3 Labeled Peptides and Proteins.

  2016cites this paper
• Production of scFvs as anti-ABO antibodies antagonist for prevention of hemolytic transfusion reactions resulting ABO blood groups incompatibility between donor and recipient

  2016cites this paper
• Engineered IgG1‐Fc – one fragment to bind them all

  2016cites this paper
• Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.

  2016cites this paper
• Comparative Analysis of Immune Repertoires between Bactrian Camel's Conventional and Heavy-Chain Antibodies

  2016cites this paper
• Streamlining the Pipeline for Generation of Recombinant Affinity Reagents by Integrating the Affinity Maturation Step

  2015cites this paper
• A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins

  2015cites this paper
• Structural Characterization of Nanoyeast Single-Chain Fragment Variable Affinity Reagents

  2015cites this paper
• Bacterial secretion of soluble and functional trivalent scFv-based N-terminal trimerbodies

  2015cites this paper
• Functional stability of 3D8 scFv, a nucleic acid-hydrolyzing single chain antibody, under different biochemical and physical conditions.

  2015cites this paper
• Expression and significance of MOC‐31 and calretinin in pleural fluid of patients with lung cancer

  2015cites this paper
• Increased Fab thermoresistance via VH-targeted directed evolution.

  2015cites this paper
• Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display system

  2015cites this paper
• One-step immunoassay for tetrabromobisphenol a using a camelid single domain antibody-alkaline phosphatase fusion protein.

  2015cites this paper
• Complexes of magnetic nanoparticles and scFv antibodies for targeting and visualizing cancer cells

  2015cites this paper
• Preliminary Assessment of Various Additives on the Specific Reactivity of Anti- rHBsAg Monoclonal Antibodies

  2015cites this paper
• Nanobodies and recombinant binders in cell biology

  2015influential citation
• Isolation of a new human scFv antibody recognizing a cell surface binding site to CEACAM1. Large yield production, purification and characterization in E. coli expression system.

  2014cites this paper
• Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency.

  2014cites this paper
• Development of a Novel Strategy for Targeted Delivery of siRNA to B lymphocytes

  2014cites this paper
• Novel recombinant anti-HER2/neu immunotoxin: Design and antitumor efficiency

  2014cites this paper
• Determination of Supplier-to-Supplier and Lot-to-Lot Variability in Glycation of Recombinant Human Serum Albumin Expressed in Oryza sativa

  2014cites this paper
• The Preclinical and Clinical Evaluation of VB 6-845 : An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors

  2013cites this paper
• Structural annotation of human carbonic anhydrases

  2013cites this paper
• Quantitative analysis of affinity enhancement by noncovalently oligomeric ligands.

  2013cites this paper
• Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy

  2013influential citation
• Insights into human carbonic anhydrase inhibitor design

  2013cites this paper
• Engineering protein thermostability using a generic activity-independent biophysical screen inside the cell

  2013cites this paper
• An integrated approach to extreme thermostabilization and affinity maturation of an antibody.

  2013cites this paper
• Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin

  2013cites this paper
• Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display.

  2013cites this paper
• The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors

  2013cites this paper
• Biomarker Discovery in Cancer and Autoimmunity using an Affinity Proteomics Platform - a Tool for Personalized Medicine

  2013cites this paper
• Self-Assembling Complexes of Quantum Dots and scFv Antibodies for Cancer Cell Targeting and Imaging

  2012cites this paper
• Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

  2012cites this paper
• Crystal Structure of a Human Single Domain Antibody Dimer Formed through VH-VH Non-Covalent Interactions

  2012cites this paper